REGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

3.76B

-0.81%

10.705

-11.31%

3.42B

+13.07%

10.426

+26.84%

3.70B

+0.63%

11.641

-9.69%

Estimates Revision

The market is revising Upward the revenue expectations for Regeneron Pharmaceuticals, Inc. (REGN) for FY2025, with the revenue forecasts being adjusted by 2.21% over the past three months. During the same period, the stock price has changed by 31.84%.

Revenue Estimates for FY2025

Revise Upward

+2.21%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+9.79%

In Past 3 Month

Stock Price

Go Up

+31.84%

In Past 3 Month

22 Analyst Rating

Wall Street analysts forecast REGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 742.00 USD with a low forecast of 627.00 USD and a high forecast of 870.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

5 Hold

1 Sell

Moderate Buy

Current: 754.883

Low

627.00

Averages

742.00

High

870.00

Current: 754.883

Low

627.00

Averages

742.00

High

870.00

Morgan Stanley

Terence Flynn

Equal Weight

maintain

$767 -> $768

2025-12-12

New

Reason

Morgan Stanley

Terence Flynn

Price Target

$767 -> $768

2025-12-12

New

maintain

Equal Weight

Reason

Morgan Stanley analyst Terence Flynn raised the firm's price target on Regeneron to $768 from $767 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Buy

maintain

$890 -> $985

2025-12-10

New

Reason

HSBC

Price Target

$890 -> $985

2025-12-10

New

maintain

Buy

Reason

HSBC raised the firm's price target on Regeneron to $985 from $890 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

BMO Capital

Evan Seigerman

Outperform

maintain

$725 -> $850

2025-12-04

Reason

BMO Capital

Evan Seigerman

Price Target

$725 -> $850

2025-12-04

maintain

Outperform

Reason

BMO Capital analyst Evan Seigerman raised the firm's price target on Regeneron to $850 from $725 and keeps an Outperform rating on the shares. Following Regeneron's itepekimab miss in June, shares have appreciated about 50% as efforts to resolve regulatory uncertainty have started to pay dividends, the analyst tells investors in a research note. BMO adds it is raising its target price as the firm expects higher contributions from Dupixent and more moderate erosion of 2mg Eylea than previously estimated.

Canaccord

Buy

maintain

$850

2025-12-04

Reason

Canaccord

Price Target

$850

2025-12-04

maintain

Buy

Reason

Canaccord raised the firm's price target on Regeneron to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect Dupixent growth to continue to outpace EYLEA revenues, providing upside going forward. Sanofi collaboration revenue surpassed US EYLEA revenues for the first time in 1Q25, and the gap should continue to widen. As EYLEA sales continue to decline, they see Dupixent as the key growth driver going forward.

Morgan Stanley

Overweight -> Equal Weight

downgrade

$767

2025-12-03

Reason

Morgan Stanley

Price Target

$767

2025-12-03

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley downgraded Regeneron to Equal Weight from Overweight with an unchanged price target of $767. The firm sees a balanced risk/reward pending further visibility on the company's pipeline diversification. Regeneron shares have rebounded off the lows earlier this year following progress with Eylea, the analyst tells investors in a research note. Morgan Stanley cites valuation for the downgrade.

Scotiabank

Sector Perform

maintain

$650 -> $770

2025-11-24

Reason

Scotiabank

Price Target

$650 -> $770

2025-11-24

maintain

Sector Perform

Reason

Scotiabank raised the firm's price target on Regeneron to $770 from $650 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock due to "solid" execution as well as "positive vibes" following the recent upside surprise on Eylea HD approvals and ahead of 2026 data readouts, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Regeneron Pharmaceuticals Inc (REGN.O) is 16.56, compared to its 5-year average forward P/E of 16.08. For a more detailed relative valuation and DCF analysis to assess Regeneron Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

16.08

Current PE

16.56

Overvalued PE

20.04

Undervalued PE

12.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.08

Current EV/EBITDA

10.04

Overvalued EV/EBITDA

14.16

Undervalued EV/EBITDA

8.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.67

Current PS

5.13

Overvalued PS

6.91

Undervalued PS

4.44

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 167% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

REGN News & Events

Events Timeline

No data

News

5.0

12-14Barron's

Kymera Stock Soars as Secretive Hedge Fund Acquires $172 Million Stake.

6.5

12-13NASDAQ.COM

2 Compelling Reasons to Invest in Regeneron Stock Immediately

7.5

12-10Barron's

The Fed's Split on Interest Rates: Reasons Stock Markets May Climb Through 2026 and 5 Other Key Updates for Today.

People Also Watch

Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc (REGN) stock price today?

The current price of REGN is 754.8825 USD — it has increased 1.83 % in the last trading day.

What is Regeneron Pharmaceuticals Inc (REGN)'s business?

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

What is the price predicton of REGN Stock?

What is Regeneron Pharmaceuticals Inc (REGN)'s revenue for the last quarter?

Regeneron Pharmaceuticals Inc revenue for the last quarter amounts to 3.75B USD, increased 0.90 % YoY.

What is Regeneron Pharmaceuticals Inc (REGN)'s earnings per share (EPS) for the last quarter?

Regeneron Pharmaceuticals Inc. EPS for the last quarter amounts to 13.62 USD, increased 18.02 % YoY.

What changes have occurred in the market's expectations for Regeneron Pharmaceuticals Inc (REGN)'s fundamentals?

How many employees does Regeneron Pharmaceuticals Inc (REGN). have?

Regeneron Pharmaceuticals Inc (REGN) has 15106 emplpoyees as of December 15 2025.

What is Regeneron Pharmaceuticals Inc (REGN) market cap?

Today REGN has the market capitalization of 77.91B USD.